This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The launch of ChatGPT in November 2022 set off a generativeAI gold rush, with companies scrambling to adopt the technology and demonstrate innovation. Legacy chatbots, product recommendation engines, and several other useful tools may rely only on earlier forms of AI.
For example, generativeAI went from research milestone to widespread business adoption in barely a year. An IDC study found that usage of generativeAI jumped from 55% of surveyed companies in 2023 to 75% in 2024. Pharma and agriculture companies now leverage AI and gene-editing (e.g.,
Qventus platform tries to address operational inefficiencies in both inpatient and outpatient settings using generativeAI, machine learning and behavioural science. Related reading: The Weeks Biggest Funding Rounds: Data Storage And Lots Of Biotech Illustration: Dom Guzman The round was led by Kleiner Perkins.
Interestingly the model itself is not biotech-specific exactly but a derivative of the same “large language models” that have produced text production engines like GPT-3. ” Generate Biomedicines raises $370M Series B with a focus on protein-based drugs. Image Credits: Cradle.
Proteins, the natural molecules that carry out key cellular functions within the body, are the building blocks of all diseases. Characterizing proteins can reveal the mechanisms of a disease, including ways to slow it or potentially reverse it, while creating proteins can lead to entirely new classes of drugs and therapeutics.
The largest was a $275 million January Series F for Innovaccer , a San Francisco startup that makes an AI-enabled cloud tracking platform for healthcare providers. And last week, Abridge , an AI-driven platform for clinician conversations, picked up a $250 million Series D.
Gains go to states with heavily funded generativeAI startups There are, of course, many complex dynamics at play in determining why a particular state or metro area might see its startup investment fortunes rise or fall. However, in 2024 there was also a simple explanation for the funding pattern: generativeAI.
This year is shaping up as the first we’ve seen in which biotech and healthcare startups receive a majority of U.S. So far in 2024, biotech and health companies have pulled in around $5.6 The biotech sector’s comparatively strong showing comes as overall Series A dealmaking looks on track to come in a bit above last year’s totals.
The new round is bigger than the $6 billion round Elon Musk ’s generativeAI startup, xAI , officially announced in May, which up to this point was the largest round raised this year. Pacific Fusion , $900M, energy: Another huge AI-related round. Seaport Therapeutics , $225M, biotech: Seaport Therapeutics isn’t new to this list.
” Going private: A guide to PE tech acquisitions Biotech proved a surprisingly bright spot in 2022’s startup correction Image Credits: Getty Images The hard science and regulations that govern biotech companies sets them far apart from other startups. biotech deals also set new records in 2022 for both median deal size, $33.5
Last month, xAI and Anthropic raised a combined $9 billion as AI funding remained red-hot. xAI , $5B, artificial intelligence: GenerativeAI startup xAI raised $5 billion in a round valuing it at $50 billion, The Wall Street Journal reported. Other sectors, including IT management and robotics, also saw big rounds.
Wonder ’s big $700 million raise may have captured most people’s attention last month, but the story when it came for large deals was really biotech. Mirador Therapeutics , $400M, biotech: It was a huge month for big biotech raises and this was the biggest. Check out the biggest rounds of last month here.
Of course, it was led by two well-known AI startups — including xAI , which had its second massive haul of cash in just six months. xAI , $5B, artificial intelligence: GenerativeAI startup xAI raised $5 billion in a funding round valuing it at $50 billion, The Wall Street Journal reported.
Zero-based budgeting: A proven framework for extending runway 5 strategies for biotech startups to outlast a market downturn Image Credits: Getty Images Spinning up a biotech company is a massive undertaking. “The best founders look for a framework to strategically cut burn while keeping their startup’s value drivers functioning.”
We featured generativeAI companies five years before the popular investors took notice and climate tech 2.0 Clean tech – Tied in with the biotech trend, we’re seeing a continued surge in input/output companies that process waste to produce byproducts like energy and potable water. It’s a big new data rush.
The retail industry has no shortage of cases on display where generativeAI has shown tangible benefits. They had ChatGPT write the script, and other gen AI tools to create a digital person who reads the script, a scalable process with at least one measurable benefit: speed. And software code is a language.”
San Francisco-based Writer locked up a $200 million Series C that values the enterprise-focused generativeAI platform at $1.9 The new valuation is a nice uptick from the $500 million the company was valued at after a $100 million round led by Iconiq Growth last year.
Today we worry this phenomenon is playing out with enterprise adoption of generativeAI. GenerativeAI (genAI) arrived on the scene with use cases such as “support chatbots” or “talk to your documentation apps” that were so obviously useful that many companies are well on their way to taking them into production.
Biotech and AI had another strong week, as the sectors saw two big nine-figure rounds each — including one for $370 million in biotech. Candid Therapeutics , $370M, biotech: Every week there’s a big biotech raise — and this week there’s one that’s really big. Check out last week’s biggest funding rounds here.
Stability AI , the venture-backed startup behind the text-to-image AI system Stable Diffusion, is funding a wide-ranging effort to apply AI to the frontiers of biotech. “OpenBioML is one of the independent research communities that Stability supports,” Mostaque told TechCrunch in an email interview.
Not surprisingly AI led the way — as it always seems to do — with a trio of a billion-or-more rounds. xAI , $6B, artificial intelligence: Elon Musk ’s generativeAI startup, xAI , officially announced its long-awaited fundraise — making it the second-most-valuable generativeAI company in the world behind only competitor OpenAI.
Metsera , $290M, biotech: This week was a slower week than normal for biotech — as it was for most sectors — but that didn’t stop New York-based Metsera. Rivos , $250M, semiconductor: Semiconductor startups are seeing big money, in part thanks to the explosion in generativeAI.
The factories which process our food and beverages (newsflash: no, it doesn’t come straight from a farm) have to be kept very clean, or we’d all get very ill, to be blunt. That usually entails deploying all sorts of petri-dish-based microbiological monitoring, hardware and waiting for tests to return from labs.
April also saw a half-dozen rounds of a quarter-billion dollars or more, including a $1 billion round for an AI-enhanced biotech. Xaira Therapeutics , $1B, biotech: The biggest round in April was really big. The company develops power-optimized chips targeting the data analytics and generativeAI markets.
A proposed California bill that has proven controversial in the industry is looking to put safety regulations and guardrails on AI — although many companies, including OpenAI, worry it may be too burdensome to many AI firms. Sakana AI locked up a $100 million round led by Khosla Ventures , Lux Capital and New Enterprise Associates.
Formation Bio , $372M, biotech: Every week there is a big biotech raise and this week’s is really big. Formation Bio, an AI-enhanced pharma company, raised a $372 million Series D led by a16z. More and more biotech startups are using AI to help with their drug processes and investors are clearly taking note.
Pika is part of a growing group of startups building text-to-video AI software. tied) Prolific Machines , $55M, biotech: Unlike in previous weeks, there was no huge biotech round. The startup plays at a unique intersection of healthcare/biotech, AI and 3D technology.
Eight startups raised $100 million or more this week as a biotech and financial services company led the way. Yep, no huge AI raise. Scorpion Therapeutics , $150M, biotech: Yet another big biotech round. In fact, the big rounds came from everywhere, including automotive, fintech and IT software. Notice anything missing?
xAI , $6B, artificial intelligence: Elon Musk ’s generativeAI startup, xAI, officially announced its long-awaited fundraise — making it the second-most-valuable generativeAI company in the world behind only competitor OpenAI. among others. among others. The xAI round had been rumored for months. just earlier this year.
AI startup Safe Superintelligence ’s $1 billion round — for a startup that’s existed for only a few months — easily led the way. However, it wasn’t just AI that got funding in September, as biotech makes up about half the list. With the new cash, 3-month-old SSI plans to add computing power and hire new talent.
Biting into an AI Apple : Apple isn’t about to let all those other big tech companies get in on the AI fun. A new story, also by Ivan , reports that Apple is reportedly experimenting with language-generatingAI so that Siri can better understand queries. Alex found some bullish news for software companies.
Nevertheless, the week saw a $1 billion round go to yet another AI startup, and biotech and blockchain also saw some big deals. Scale AI , $1B, artificial intelligence: This week was like many — one topped with a big AI round. Check out last week’s biggest funding rounds here.
The new round is bigger than the $6 billion round Elon Musk ’s generativeAI startup, xAI , officially announced in May — which was the largest round raised this year. Kailera Therapeutics , $400M, biotech: Biotech was even bigger this week than normal. Poolside has raised $626 million since being founded in May 2023.
The quintet that did raise big were from three of the usual sectors — biotech, energy and AI — however one was from a sector we don’t normally see — a vertical farming agtech startup. FogPharma , $145M, biotech: It sure feels like this will be a big year for biotech startups, as a few make this list every week.
Andreessen co-led the Series B in AI voice software developer ElevenLabs with angel investors Nat Friedman and Daniel Gross. The firm also led the Series A in text-to-image generativeAI company Ideogram. Healthcare and AI lead The increase in funding at Series A and B in the U.S.
Key Takeaways from BioTechX 2024: A Shift Towards Realism and Practical Applications Capgemini Nov 6, 2024 Facebook Linkedin The BioTechX event in Basel in October was a major gathering for biotech and pharma professionals. Last year, we were all about the potential of large language models and generativeAI.
While there were no huge rounds like last week, money was again spread around from AI to biotech to marketing and more. Celestial AI , $175M, semiconductors: Optical interconnectivity startup Celestial AI raised a massive $175 million Series C led by Thomas Tull ’s US Innovative Technology Fund.
Top sectors Biotech and healthcare was the leading sector by funding amount in April. AI companies raised $3.9 Not growing, not slowing The launch of generativeAI has led to the creation of new startups in this cycle. Companies in that space raised $5.7 billion, or around 26% of all funding, according to Crunchbase data.
While GenerativeAI is buzzy right now, what OpenAI, Microsoft and Google are doing may be only part of the story. He says the technology could also be used to study dementia and even ‘brute force’ test the compounds that we have discovered using Quantum Computing and GenerativeAI.”
Investors certainly put their money everywhere, from biotech to productivity tools, but they didn’t shell out a lot. Pathalys Pharma , $105M, biotech: Raleigh, North Carolina-based Pathalys Pharma isn’t new to this list — it topped it early last year. Another slow week with only three companies raising rounds of more than $100 million.
Generate invests in an array of infrastructure projects, from community solar systems to municipal wastewater treatment to electrifying fleets. Kore.ai , $150M, artificial intelligence: Another week and another big round for a generativeAI startup. AI enterprise conversational platform Kore.ai billion, per Crunchbase.
Formation Bio , $372M, biotech: Formation Bio, an AI-enhanced pharma company, raised a $372 million Series D led by a16z. More and more biotech startups are using AI to help with their drug processes and investors are clearly taking note. Founded in 2011, the company has raised $1.4 billion, per Crunchbase.
Terray Therapeutics , $120M, biotech: Los Angeles-based Terray Therapeutics, a biotech startup developing small molecule drug therapeutics, raised a $120 million Series B led by new investor Bedford Ridge Capital and existing investor NVentures. Founded in 2021, the company has raised nearly $318 million, per Crunchbase.
The barely more than 1,000 deals announced last quarter was the lowest total for rounds going to AI-related startups in years. Of course, some of the biggest include Elon Musk ’s generativeAI startup, xAI , officially announcing its long-awaited $6 billion fundraise, CoreWeave locking up $1.1
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content